Velcade Therapy for Severe IgA Nephropathy
This exploratory single center, open-label, single treatment group assignment, safety and
efficacy study will enroll 10 patients with severe IgA nephropathy. Subjects will receive 1
cycle of Velcade® to induce clinical remission. Follow-up visits will occur monthly for a
For this pilot study, the proportion of patients with clinical remission or partial response
will be analyzed.
Monetary compensation will be provided to study participants.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Quantification of urinary protein will be made after treatment by measuring 24 hr urine protein.
Choli Hartono, MD
The Rogosin Institute
United States: Institutional Review Board
|The Rogosin Institute||New York, New York 10021|